THX Pharma Société Anonyme (EPA:ALTHX)
France · Delayed Price · Currency is EUR 2.500
-0.090 (-3.47%)
Jan 30, 2026, 5:35 PM CET
THX Pharma Société Anonyme Company Description
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease.
The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025.
The company was founded in 2013 and is headquartered in Lyon, France.
THX Pharma Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Mathieu Charvériat |
Contact Details
Address: 60, Avenue Rockefeller Lyon, 69008 France | |
| Phone | 33 1 88 89 70 31 |
| Website | theranexus.com |
Stock Details
| Ticker Symbol | ALTHX |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013286259 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Julien Veys | Deputy Chief Executive Officer, Chief Operating Officer and Director |
| Mathieu Charvériat | Co-Founder, Chief Executive Officer and Chairman |
| Franck Mouthon | Co-Founder and Director |
| Christine Placet | Administrative and Financial Director |
| Francoise Vincent-Larrode | Director of Human Resources |
| Marie Sebille | Chief Medical Officer |